The update published this week in JAMA Neurology evaluates the safety, efficacy, and durability of MS disease stabilization achieved in the three years after the HDIT/HCT therapy was administered to a group of 25 participants, 24 of whom ultimately received the experimental treatment. However RRMS patient participants in a clinical trial who received high-dose immunosuppressive therapy (HDIT) with autologous hematopoietic cell transplant (HCT) may, by contrast, experience sustained remissions in cases of MS treated early. The coauthors observe that most patients with relapsing-remitting multiple sclerosis who are treated with approved disease-modifying therapies will experience breakthrough disease and accumulate neurologic disability. Luke’s Medical Center, Denver, and coauthors report on the safety, efficacy and sustainability of MS disease stabilization though three years after the procedures. Nash, M.D. of the Colorado Blood Cancer Institute at Presbyterian/St. In an article study, lead author Richard A. Published online DecemDOI: 10.1001/jamaneurol.2014.378) is coauthored by Richard A. Nash, MD, George J. Hutton, MD Michael K. Racke, MD Uday Popat, MD Steven M. Devine, MD Linda M. Griffith, MD, PhD Paolo A. Muraro, MD, PhD Harry Openshaw, MD Peter H. Sayre, MD, PhD9,10 Olaf Stüve, MD, PhD11,12,13 Douglas L. Arnold, MD Meagan E. Spychala, DrPH Kaitlyn C. McConville, MS Kristina M. Harris, PhD Deborah Phippard, PhD George E. Georges, MD, Annette Wundes, MD George H. Kraft, MD, MS, and James D. Bowen, MD, representing 22 different medical research institutions in the U.S.Canada, and the U.K. “We first did this in animal models of autoimmune diseases such as (experimental autoimmune encephalomyelitis), an animal model of multiple sclerosis, and long story short, it worked.The Open Source research update, entitled “High-Dose Immunosuppressive Therapy and Autologous Hematopoietic Cell Transplantation for Relapsing-Remitting Multiple Sclerosis (HALT-MS) – A 3-Year Interim Report,” (JAMA Neurol. “It occurred to me that losing an immune response to self-antigens in an autoimmune disease is exactly what you want,” Burt said. The professor of medicine at Feinberg said the idea came to him when he was a fellow at Johns Hopkins, and patients had to be re-immunized for childhood vaccines after receiving transplants for cancer. Richard Burt pioneered this approach, also known as hematopoietic stem cell transplantation. The transplant procedure involves collecting stem cells from patients before “knocking down” their immune system and then giving the stem cells back to them after a few days of drugs, when the immune system resets.ĭr. Researchers discovered that following a stem cell transplant, AQP4 disappeared in the blood of patients. What sets it apart from MS and other autoimmune diseases is that it has a biological marker known as AQP4, which increases the chances of a relapse. A new study from Northwestern Medicine and the Mayo Clinic found that a stem cell transplant is capable of reversing autoimmune diseases like neuromyelitis optica, an aggressive neurological disease that causes many patients to lose their sight and ability to walk within five years following diagnosis.įormerly classified as a subtype of multiple sclerosis, neuromyelitis optica is now categorized as a separate disease.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |